Product Images Oxaliplatin

This is a description of Oxaliplatin injection, USP, with a dosage of 100mg/20ml and a concentration of 5mg/ ml. It comes in a vial containing Oxaliplatin USP 100mg and Water for Injection, USP (20ml). It is a cytotoxic agent, which should be administered for intravenous use only between 15 to 30°C (59 to 85°F). It is a preservative-free aqueous solution, and it should be protected from high temperatures. The package insert should be read to learn more about required conditions, and it should not be mixed or added to sodium chloride or chloride-containing solutions. The solution should not be frozen. Its manufacturer is Qily Pharmaceutical (Hainan) Co. Ltd in China, and the product is distributed by BluePoint Laboratories.*

This is a description of a medication labeled NDC 6800146836 RxOnly, which contains Cyclostatic Agent Ol Pramacsucal (Hainan) Go. Ltd. The medication is in a 50 ml injection, USP, and each vial comes from Haikou, 570314, China. The package insert contains vital information such as storage requirements, caution, temperature range (between 15 -30°C), control measures for aqueous solutions, and the discarding of unused portions. The medication is not to be mixed with SODIUM CHLORIDE or stored in SINGLE-DOSE Vials.*

This is a chart showing DFS (Disease-Free Survival) Probability with percentages ranging from 0.0 to 1.0, displayed by different time points. The table also includes the number of patients at risk and a stratified log-rank test result. The quality is poor, making specific details unclear.*

This text contains information related to "DFS Probability", which appears to be a medical or scientific report. The table provided shows different stages and probability scores for DFS (Disease-Free Survival) with treatment arms FOLFOX4 and LVSFU2. The Logrank test result indicates a p-value of 0.005. The text is not readable in a few places due to the errors.*

This text seems to be describing the median survival rates of patients undergoing treatment with two different drugs: Oxaliplatin Injection USP + 5-FULV and Oxaliplatin Injection USP + irinotecan. The median survival rate for the former group is about 19.4 months, while the latter group had a median survival rate of about 17.6 months. The text also mentions a statistical analysis that suggests the difference in survival rates between these two groups is significant. Finally, a time axis is given, displaying the months of survival.*